Form 4 for EYPT EyePoint, Inc.
Accepted 2024-01-25 00:00:00 ET · period of report 2024-01-23 · accession 0001562180-24-000636 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| DMT | 2024-01-25 | 2024-01-23+ | EYPT | Lurker Nancy | Executive Vice COB, Dir | S - Sale | $24.98 | -35.0K | 165.4K | -17% | -$874.2K |
| DTI | 2024-01-25 | 2024-01-24 | EYPT | Lurker Nancy | Executive Vice COB, Dir | G - Gift | $0.00 | +112.7K | 112.7K | New | $0 |
| DT | 2024-01-25 | 2024-01-24 | EYPT | Lurker Nancy | Executive Vice COB, Dir | G - Gift | $0.00 | -112.7K | 338.1K | -25% | $0 |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2024-01-24 | S | D | 29,956 | $24.98 | 135,441 | D | — | — | (F2) The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $24.95 to $25.24. The reporting person undertakes to provide EyePoint Pharmaceuticals Inc., any security holder of EyePoint Pharmaceuticals Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote. |
| 2 | Common | Common Stock | 2024-01-23 | S | D | 5,044 | $24.97 | 165,397 | D | — | — | (F1) The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $24.95 to $25.00. The reporting person undertakes to provide EyePoint Pharmaceuticals Inc., any security holder of EyePoint Pharmaceuticals Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote. |
| 3 | Derivative | Stock Option (Right to Buy) | 2024-01-24 | G | A | 112,700 | $0.00 | 112,700 | I | $3.26 · — to 2033-01-05 | 112,700 Common Stock | (F5) The option to purchase vests and becomes exercisable as follows: 25% at January 6th, 2024 and the remainder ratably, on a monthly basis, over the remaining three years. |
| 4 | Derivative | Stock Option (Right to Buy) | 2024-01-24 | G | D | 112,700 | $0.00 | 338,100 | D By Family Trust | $3.26 · — to 2033-01-05 | 112,700 Common Stock | (F3) These securities are held in a trust for the benefit of the reporting person's children. The reporting person's spouse is trustee of the Family Trust. The reporting person disclaims beneficial ownership of these securities, and the filing of this report is not an admission that the reporting person is the beneficial owner of these securities for purposes of Section 16 or for any other purpose. (F5) The option to purchase vests and becomes exercisable as follows: 25% at January 6th, 2024 and the remainder ratably, on a monthly basis, over the remaining three years. |